Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis - Forecast to 2026 - ResearchAndMarkets.com
Aug. 08, 2018
DUBLIN--(BUSINESS WIRE)--Aug 8, 2018--The "Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
This report gives comprehensive insights on the various drugs being developed for the treatment of NASH.
The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical).
The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs.
The report also covers some of the hot targets in research for NASH treatments and NASH related biomarkers.
Some of the key sections covered in the report are given below:Epidemiology In this section, epidemiology of NASH is reviewed to understand potential significance and impact of the disease.Global & US prevalence rates. Hot Targets, Mechanisms & Therapies In this section, various NASH associated targets, mechanism and upcoming therapies are discussed. Also, covers novel targets in early research for NASH along with disease progression biomarkers associated with NASH (Inflammatory, apoptosis, fibrosis). Pipeline Analysis Pipeline analysis was carried to get deeper insights on various treatment modalities in discovery, preclinical & development section, pipelines from major companies were identified and Potential targets were reported along with Mechanism of action, Current development status & nature of molecule. Pipeline analysis by developmental stage (Discovery to Clinical development).Pipeline analysis by modalities Monoclonal Antibodies pipeline analysis RNA-therapeutics pipeline analysis Recombinant protein pipeline analysis Pipeline analysis by leading players & Target analysisDrug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic and Metabolic)
Key Topics Covered
1. Report DescriptionCauses & Symptoms Diagnosis Unmet Needs Current Therapies
2. Hot Targets, Mechanisms & TherapiesNovel Disease Mechanisms & Therapies Leading Targets Of NASH Novel Targets Of NASH Nash Biomarkers Genes Involved In NASH
3. Market DataForecasting Model Market Dynamics Market Sizing And Peak Sales NASH Deals Funding Scenario
4. Pipeline AnalysisDevelopment Stage Leading Players Molecule Type Target Analysis Clinical Update On Phase 3 Molecules Innovative Approaches
5. Small MoleculesPipeline Competitive Landscape
6. Large MoleculesAntibodies PipelineCompetitive Analysis Recombinant Proteins PipelineCompetitive Analysis RNA-Based Therapy Pipeline Competitve Landscape Pipeline
8. Other MoleculesPipeline
9. NASH Drug Analysis Based On Mechanism (Clinical)
10. Major PlayersCompany Profiles OverviewPipelineDeals
Companies FeaturedAlbireo Pharma Allergan Plc Boehringer Ingelheim GmbH Bristol-Myers Squibb Cerenis Therapeutics Connexios Life Systems Enanta Pharmaceuticals GENFIT Gilead Sciences Inc NGM Biopharmaceuticals Novartis AG Novo Nordisk Pfizer Promethera Biosciences Prometic Lifesciences Taiwanj Pharmaceuticals Terns Pharmaceuticals VBL Therapeutics Viking Therapeutics
For more information about this report visit https://www.researchandmarkets.com/research/2zzbp8/nonalcoholicsteato?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180808005270/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Liver and Kidney Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/08/2018 05:04 AM/DISC: 08/08/2018 05:04 AM